Perytor Therapeutics

Perytor Therapeutics was a private U.S. biotechnology startup based in San Antonio, Texas focused on developing a placenta-derived biologic intended to reduce inflammation while promoting tissue regeneration. The company positioned its lead approach as an alternative to steroids and live stem cell therapies by isolating an active agent from human placental tissue rather than administering living cells. Public descriptions highlighted potential applications in musculoskeletal disorders such as degenerative joint disease and tennis elbow, as well as inflammatory lung conditions including chronic obstructive pulmonary disease. The business appeared to be at an early development stage, with references to a small blinded exploratory study and a longer-term plan to create a synthetic version of its biologic. Corporate registry data indicate the entity later fell into forfeited status, suggesting it is not currently active.